Premium
3‐Methylhistidine and cardiolipin as biomarkers of zinc deficiency (122.3)
Author(s) -
NkrumahElie Yasmeen,
Choi Jaewoo,
Kirkwood Jay,
Stevens Fred,
Tanguay Robert,
Chung Carolyn,
King Janet,
Brown Kenneth,
Ho Emily
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.122.3
Subject(s) - zinc deficiency (plant disorder) , zinc , cardiolipin , endocrinology , medicine , catabolism , biology , metabolism , chemistry , biochemistry , phospholipid , organic chemistry , membrane
The global epidemic of zinc deficiency is likely contributing to the development of chronic disorders such as cancer, insulin resistance, and immune dysfunction, though reliable biomarkers for human zinc deficiency are not currently available. To discover novel indicators of zinc deficiency in humans, untargeted metabolomic and lipidomic profiles were assessed from plasma samples collected during a controlled feeding trial in healthy men to induce zinc depletion at baseline (2 wk, 11mg Zn/d), zinc‐depletion (0.6mg Zn/d for 1 wk and 4mg Zn/d for 5 wk), and zinc‐repletion (4 wk, 11mg Zn/d). 3‐methylhistidine, an indicator of human muscle catabolism, was confirmed as the most significantly increased (8‐fold change, P<0.0001) metabolite resulting from zinc depletion, which may indicate endogenous mechanisms for maintaining plasma zinc homeostasis. Lipidomic analysis indicated that dietary zinc deficiency resulted in 5‐fold decreases in sphingomyelin (P=0.039) and phosphatidylcholine (P=0.0298) species, with a 10‐fold increase in cardiolipin (P=0.03766). Elevated levels of cardiolipin and zinc deficiency have both been associated with hyperthyroidism. Thus, this research is significant not only in its identification of clinical biomarkers of zinc deficiency, but may also contribute to unraveling the mechanisms associated with dietary zinc deficiency and health outcomes. Grant Funding Source : Supported by: USANA Health Sciences, T32 ES007060 & P30 ES000210